CD274 and adrenal cortex carcinoma: These observations lend further support for the use of PD-1 targeted therapies (pembrolizumab, nivolumab, and cemiplimab), as compared to PD-L1 inhibitors (atezolizumab, avelumab, and durvalumab), for the treatment of R/M ACC.